Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharina A Mayer

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|July 24, 2019
Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host InteractionKatharina A Mayer, Johannes Stöckl, Gerhard J Zlabinger, et al.
Immunity, Inflammation and Disease|October 31, 2020
Cesarean section and risk of allergies in Ecuadorian children: A cross-sectional studyAmélie Gorris, Gabriela Bustamante, Katharina A Mayer, et al.
Expert Opinion on Emerging Drugs|June 18, 2022
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trialsKatharina A Mayer, Klemens Budde, Bernd Jilma, et al.
Current Opinion in Organ Transplantation|December 14, 2020
New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatmentKatharina A Mayer, Konstantin Doberer, Farsad Eskandary, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 30, 2025
Targeting CD38 in Antibody-Mediated RejectionKatharina A Mayer, Klemens Budde, Matthias Diebold, et al.
Transplantation|August 28, 2024
Chronic Rejection After Kidney TransplantationMatthias Diebold, Katharina A Mayer, Luis Hidalgo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2016
The AMP analog AICAR modulates the Treg/Th17 axis through enhancement of fatty acid oxidationGuido A Gualdoni, Katharina A Mayer, Lisa Göschl, et al.
Kidney International|April 20, 2025
Clinical utility of donor-derived cell-free DNA testing for kidney transplant monitoring in selected patientsKlemens Budde, Bilgin Osmanodja, Eva Schrezenmeier, et al.
Expert Opinion on Investigational Drugs|February 10, 2025
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluationKatharina A Mayer, Klemens Budde, Martina Schatzl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 3, 2024
Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection: Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional DeclineCarsten T Herz, Matthias Diebold, Alexander Kainz, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|July 24, 2019
Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host InteractionKatharina A Mayer, Johannes Stöckl, Gerhard J Zlabinger, et al.
Immunity, Inflammation and Disease|October 31, 2020
Cesarean section and risk of allergies in Ecuadorian children: A cross-sectional studyAmélie Gorris, Gabriela Bustamante, Katharina A Mayer, et al.
Expert Opinion on Emerging Drugs|June 18, 2022
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trialsKatharina A Mayer, Klemens Budde, Bernd Jilma, et al.
Current Opinion in Organ Transplantation|December 14, 2020
New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatmentKatharina A Mayer, Konstantin Doberer, Farsad Eskandary, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 30, 2025
Targeting CD38 in Antibody-Mediated RejectionKatharina A Mayer, Klemens Budde, Matthias Diebold, et al.
Transplantation|August 28, 2024
Chronic Rejection After Kidney TransplantationMatthias Diebold, Katharina A Mayer, Luis Hidalgo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2016
The AMP analog AICAR modulates the Treg/Th17 axis through enhancement of fatty acid oxidationGuido A Gualdoni, Katharina A Mayer, Lisa Göschl, et al.
Kidney International|April 20, 2025
Clinical utility of donor-derived cell-free DNA testing for kidney transplant monitoring in selected patientsKlemens Budde, Bilgin Osmanodja, Eva Schrezenmeier, et al.
Expert Opinion on Investigational Drugs|February 10, 2025
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluationKatharina A Mayer, Klemens Budde, Martina Schatzl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 3, 2024
Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection: Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional DeclineCarsten T Herz, Matthias Diebold, Alexander Kainz, et al.
Pageof 3